Menu

Merck

Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congress™ 2017

KENILWORTH, N.J. April 5, 2017 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company’s chronic hepatitis C virus (HCV) clinical development programs as well as real-world studies on ZEPATIER® (elbasvir and grazoprevir) 50mg/100mg tablets will be presented at the upcoming International Liver Congress™ […]

Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)

Clinical Program Now Includes Seven Registrational Trials Across Five Tumor Types WILMINGTON, Del. & KENILWORTH, N.J. March 31, 2017 – Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme […]

European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Recommendation Is for Adult Patients Who Have Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who Are Transplant-Ineligible and Have Failed BV KENILWORTH, N.J. March 24, 2017 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the […]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy

Only Anti-PD-1 Therapy Approved for the Treatment of Patients with Difficult-to-Treat cHL Regardless of Prior Stem Cell Transplantation or Use of Brentuximab Vedotin KENILWORTH, N.J. March 14, 2017 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the […]

Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer

KENILWORTH, N.J. March 14, 2017 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for previously treated patients with advanced microsatellite instability-high (MSI-H) […]

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes

Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA ® (sitagliptin) or Metformin KENILWORTH, N.J. & NEW YORK – March 6, 2017 –(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review […]

Merck Announces Findings for Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates of Sustained Virologic Response in People with Genotypes 1, 2 or 3 Infection

, , ,

Phase 2 Data Presentations at The Liver Meeting ® Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed November 13, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the presentation of results from three […]

Merck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable and Underserved U.S. Communities

, , , ,

Merck Announces Presentation of New Findings for ZEPATIER™ (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting® November 12, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from multiple analyses at The Liver Meeting® 2016, which provide additional evidence supporting the […]

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Overall Survival Compared to Chemotherapy in Previously Treated Patients with Advanced Bladder (Urothelial) Cancer

, , ,

First Presentation of Data from Phase 3 KEYNOTE-045 Study Presented at the Society for Immunotherapy of Cancer’s (SITC) 31 st Annual Meeting November 12, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-045 study investigating the use of KEYTRUDA® (pembrolizumab), the company’s […]

New KEYTRUDA® (pembrolizumab) Data Accepted for Presentation at SITC 2016 Annual Meeting

, ,

First Presentation of Overall Survival Data in Patients with Advanced Bladder (Urothelial) Cancer from KEYNOTE-045 Study November 7, 2016 – KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new data investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced […]

‹ 1 2 3 4›»